Cathie Wood’s ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in their portfolio holdings. The trades indicate a continued interest in biotech with a notable sell-off in the healthcare services sector.
The most significant trade of the day was the sale of 35,357 shares of Accolade Inc (NASDAQ:) by the ARKG ETF, amounting to $243,609. This move follows a pattern of reduction in ARK’s position in Accolade, as the fund has been consistently selling shares of the company since last week, with a substantial offload of 284,775 shares on Friday, January 17th, 2025, valued at $1,962,099.
Simultaneously, ARK has been bolstering its stake in Absci Corp (NASDAQ:), with the ARKG ETF purchasing 20,310 shares worth $81,849. This buy is part of a recent trend, as ARK previously acquired 50,53 and 79,411 shares of Absci on January 22nd and 21st, respectively, indicating a growing confidence in the biotech firm.
Another notable trade was the sale of Elbit Systems Ltd (NASDAQ:) shares, with ARKQ ETF selling 499 shares and ARKX (NYSE:) ETF parting with 151 shares, totaling a combined value of $197,632. This continues a sell-off trend from previous days, including the sale of 400 shares on January 22nd and 2,701 shares on January 21st.
While the day’s trades were diverse, the focus on biotech and healthcare-related stocks remains evident. Investors following ARK’s movements can observe a clear pattern of divesting from certain healthcare service providers while increasing positions in select biotech companies, showcasing Cathie Wood’s investment strategy adapting to the ever-changing market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
